Balance of Power measures where the close finished relative to the open, showing whether buyers or sellers controlled the session.
Daily Balance Of Power Analysis Today
Balance of Power measures where the close finished relative to the open, showing whether buyers or sellers controlled the session. The current Daily Balance Of Power for Denali Therapeutics is 0.2336. This reading indicates elevated price movement across the session.
On May 06 2026 Denali Therapeutics was traded for 18.92 at the closing time. The top price for the day was 19.40 and the lowest listed price was 18.33 . Trading activity remained within a narrow range during the period. Price movement on May 6, 2026 remained within defined bounds. The net trading delta against the current closing price is 1.22% .
BOP trending toward the high of its range signals sustained buying pressure on Denali Therapeutics. A decline from positive toward zero suggests weakening demand. Conversely, BOP moving from deeply negative toward zero indicates diminishing selling pressure. Divergence between BOP direction and price direction may signal a pending reversal.
Related Price-Series Methods for Denali Therapeutics
These methods summarize the same price history through smoothing, range, and momentum calculations. Reviewing them alongside Daily Balance Of Power helps compare stable sessions with periods of wider price movement in Denali Therapeutics.
Checking Denali Therapeutics against related firms within the Health Care space reveals where the stock stands among peers. Checking Denali Therapeutics against peers on P/E, margins, and return on equity helps put its position in context. Peer review is most informative when paired with absolute pricing and trend checks.
For investors tracking Denali Therapeutics, market strength indicators offer quantitative evaluation of stock behavior. When Rate of Change diverges from price direction, it often signals weakening momentum before a visible reversal in Denali Therapeutics. These metrics are particularly useful when Denali Therapeutics stock shows divergence from broader market trends. These metrics provide additional context for comparing intraday conviction with broader price movement in Denali Therapeutics.
Analyzing Denali Therapeutics' basic risk indicators provides a structured view of the risk-return trade-off for denali stock. Expected shortfall estimates the average loss in the worst-case tail scenarios, going beyond what standard deviation alone captures for Denali Therapeutics. Semi-deviation focuses exclusively on returns below the mean, making it a more conservative risk gauge for Denali Therapeutics than full standard deviation. The risk-return trade-off for denali stock becomes clearer when downside and total variance are viewed together.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Denali Therapeutics Short Properties
Reviewing short-oriented indicators for Denali Therapeutics is useful because long and short participants often create very different signals for timing and volatility. This is applicable when the question is whether bearish pressure is starting to shape the market's reaction function.
Common Stock Shares Outstanding
175.46 million
Cash And Short Term Investments
867.88 million
More Resources for Denali Stock Analysis
A full view of Denali Therapeutics is built from its financial statements and trend data. These measures show how earnings and operations are structured.